These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33498392)

  • 1. Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer's Dementia Treatment, on Intestinal Properties of the Mouse.
    Nguyen VTT; Sallbach J; Dos Santos Guilherme M; Endres K
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
    Enz A; Gentsch C
    Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
    Kondak C; Riedel G; Harrington CR; Wischik CM; Klein J
    J Neurochem; 2022 Jan; 160(2):172-184. PubMed ID: 34855998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study.
    Shearman E; Rossi S; Szasz B; Juranyi Z; Fallon S; Pomara N; Sershen H; Lajtha A
    Brain Res Bull; 2006 Mar; 69(2):204-13. PubMed ID: 16533671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.
    Wenk GL; Quack G; Moebius HJ; Danysz W
    Life Sci; 2000 Feb; 66(12):1079-83. PubMed ID: 10737358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
    Jürgenson M; Zharkovskaja T; Noortoots A; Morozova M; Beniashvili A; Zapolski M; Zharkovsky A
    J Pharm Pharmacol; 2019 Nov; 71(11):1695-1705. PubMed ID: 31531878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.
    Maurice T
    Behav Brain Res; 2016 Jan; 296():270-278. PubMed ID: 26386305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.
    Woodruff-Pak DS; Tobia MJ; Jiao X; Beck KD; Servatius RJ
    Neuropsychopharmacology; 2007 Jun; 32(6):1284-94. PubMed ID: 17119537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
    Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New anti-AD drugs--their possibilities and issues].
    Nakamura Y
    Seishin Shinkeigaku Zasshi; 2012; 114(3):255-61. PubMed ID: 22568059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease.
    Kaniakova M; Nepovimova E; Kleteckova L; Skrenkova K; Holubova K; Chrienova Z; Hepnarova V; Kucera T; Kobrlova T; Vales K; Korabecny J; Soukup O; Horak M
    Curr Alzheimer Res; 2019; 16(9):821-833. PubMed ID: 30819076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.